| LABORATORY DATA & INFORMATION MANAGEMENT About the Client: The client is a global multi-billion dollar pharmaceutical company with multiple products in the market and more than 75 products in development phase and clinical trials. The Engagement: The objective of this project was to provide a risk assessment of the clients’ internal custom genomic/sequencing platform from a business and technological perspective. In order to attain the project objectives, Tribiosys conducted its analysis through a combination of facilitated discussions with the necessary user groups and financial personnel and a hands-on analysis of the documentation and applications comprising the platform. As a result, Tribiosys was able to identify business risk by conducting an analysis of the strategic implications of continuing to use and support a legacy platform, the capacity of the platform to support potential future changes to the sequencing process and an assessment of quality issues likely to emerge in the future if the current system is continued. In addition, Tribiosys identified current fixed and variable costs associated with the platform, determined the impact to each cost category to maintain or modify current components, and estimated the financial costs involved to roll-in enhancements to the platform including hardware and personnel costs. The technical risk assessment included identification of disaster recovery capabilities, ability to respond to critical failures within the software, ability to perform periodic system maintenance and enhancement and the ability to respond to performance degradation. Following the client’s assessment of the project recommendations, Tribiosys was engaged to perform a follow-on project to identify, assess and recommend a replacement system. Tribiosys met with users to identify the current and anticipated future workflows and processes, and to identify the requirements for a sequencing LIMS. The information gathered during these meetings was analyzed and used to generate a vendor script for use during the demonstration and evaluation process. Tribiosys and the client jointly carried out day-long evaluations of each product. These evaluations consisted of formal demonstrations followed by validation of instrument interfacing capabilities with the instruments in the sequencing laboratory where appropriate. Following the evaluations, the selected vendors were invited to submit a quote for their product, along with hardware, software, maintenance and support costs. A review of the data migration needs was conducted in addition to a direct comparison of the competing products’ functionality and costs. Recommendations for most appropriate solution were presented in addition to options and timelines for migrating from the current sequencing platform to the recommended system. About the Client: The client is a large biotechnology company that develops cancer treatment solutions by combining functional genomics and antigen-discovery technology with its proprietary biotechnology capabilities. The Engagement: Tribiosys was engaged by the client to develop a strategy and gather requirements for an application to house biological pathway data. The specific goals of the engagement were to work with champions within the entire client organization who heavily use biological pathway information and their research groups to develop a business case for using biological pathways as a central tool in the client’s business processes, as a knowledge management tool as well as to gather requirements from the users and super-users (the Bioinformatics department). Tribiosys also developed a roadmap for the development and implementation of the proposed solution About the Client: The client is a four-year-old biopharmaceutical company with about 90 employees. The company uses a network-biology based approach to rapidly identify and validate targets as well as to synthesize new chemical entities against these targets. The Engagement: Tribiosys defined an approach for an
integrated view of research and early development data within the scientific
groups to alleviate a major bottleneck in the R&D process. During
this engagement, Tribiosys investigated the existing architecture and
applications within use at the company to identify the best migration
path towards the solution. The existing infrastructure and applications
were analyzed for their extensibility, maintainability, scalability and
flexibility. Tribiosys worked with the IT and bioinformatics groups at
the company to extend the existing data model to allow for fine grained
experimental record tracking and integrate bioinformatics data relating
to metabolic pathways, genes and proteins from external data sources.
About the Client: The client is a 13-year-old biopharmaceutical company in the protein crystallography and formulation business. The Engagement: Tribiosys was engaged by the client
to develop an understanding of the scientific processes underlying the
business process within the company. The specific goal of the engagement
was to identify a regulatory compliant scientific data management product
that could be rapidly deployed within the company while offering an upgrade/customization
path that will meet the future needs of the company. As a result of extensive
of discussions, a number of high level user and functional requirements
were identified. These requirements were prioritized based on their importance
to the overall scientific and business processes and their impact to the
near, mid and long-term business goals of the company. Based on these
prioritized requirements product selection was accomplished. Tribiosys
and the client have also jointly developed an implementation plan for
the company for this initiative that includes a roll out and customization
plan for the different functional groups within the company over the next
18 months.
Copyright (C) 2004 - 2006 Tribiosys, Inc. |